Lilly(Eli) & Co

NYSE:LLY   3:59:59 PM EDT
242.31
+3.33 (+1.39%)
Products, Regulatory

Loxo Oncology At Lilly Announces Updated Data From The Phase 1/2 Bruin Clinical Trial For Loxo-305

Published: 12/07/2020 16:36 GMT
Lilly(Eli) & Co (LLY) - Loxo Oncology at Lilly Announces Updated Data From the Phase 1/2 Bruin Clinical Trial for Loxo-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting.
Eli Lilly and Co - Phase 3 Program in Cll/sll to Be Initiated in 2021, Including a Superiority Head-to-head Trial Comparing Loxo-305 Versus.
Ibrutinib.
Eli Lilly and Co - Similar Overall Response Rates Observed in Patients Previously Treated With All Classes of Available Therapy in Study.